Want to see CYTOF full AI Analyst Report?
Altamira Therapeutics (CYTOF) Income Statement
Altamira Therapeutics Income Statement
Last quarter (Q2 2023), Altamira Therapeutics's total revenue was $52.73K, a decrease of 63.73% from the same quarter last year. In Q2, Altamira Therapeutics's net income was $-2.71M. See Altamira Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| $ 0.00 | $ 305.62K | $ 63.88K | $ 174.47K | $ -56.00K | |
| $ 0.00 | $ -1.14M | $ -2.18M | $ 174.47K | $ -56.00K | |
| $ 6.54M | $ 24.99M | $ 14.92M | $ 5.46M | $ 7.26M | |
| Depreciation and Amortization | $ 5.92M | $ 118.89K | $ 76.36K | $ 20.04K | $ 30.82K |
| $ -1.35M | $ -17.64M | $ -6.72M | $ -5.26M | $ -7.24M | |
| $ -5.92M | $ -26.13M | $ -17.10M | $ -5.28M | $ -7.26M | |
| $ -1.35M | $ -645.64K | $ -1.46M | $ -2.94M | $ 433.41K | |
| $ -7.27M | $ -26.54M | $ -17.37M | $ -8.22M | $ -6.83M | |
| $ -7.27M | $ -26.53M | $ -17.39M | $ -8.20M | $ -6.63M | |
| Per Share Metrics | |||||
| Basic EPS | $ -14.81 | $ -582.58 | $ -525.13 | $ -545.41 | $ -455.96 |
| Diluted EPS | $ -14.80 | $ -582.58 | $ -525.13 | $ -545.41 | $ -455.96 |
| Weighted Average Shares Outstanding | 491.00K | 45.54K | 33.12K | 15.04K | 14.54K |
| Weighted Average Shares Outstanding (Diluted) | 491.26K | 45.54K | 33.12K | 15.04K | 14.54K |
Currency in CHF